QNTM

AI Memo

Quantum Biopharma Subordinate Voting Shares

As of 2026-10-24/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-24 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Lucid-MS Phase 2 site activation and first enrollment • 2027-03-31

Base target: $2 / p=45% prob

Biggest risk

The agreement establishes study start-up, not enrollment or efficacy. Trial execution may increase spending, while the reported runway is conditional and includes digital assets. Financing dilution remains a material risk.

Invalidation

Break below $1 or thesis failure.

What would change my mind?

FDA clearance and the contracted Phase 2 start-up move Lucid-MS closer to testing in patients. Lower reported operating expenses and cash use provide some near-term funding flexibility. [#SEC-6K-2026-10-06] [#SEC-6K-2026-08-14] https://www.sec.gov/Archives/edgar/data/1771885/000117184326006429/exh_991.htm https://www.sec.gov/Archives/edgar/data/1771885/000117184326005524/exh_991.htm

Research note

Recommendation

—

Confidence

medium

As of

2026-10-24

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Runway and financing reassessment as trial spending rises
Lucid-MS Phase 2 clinical evidence
FDA clearance and the contracted Phase 2 start-up move Lucid-MS closer to testing in patients.

BearKey bullets

First-patient enrollment, trial completion and clinical benefit remain unconfirmed.
Phase 2 costs may accelerate cash use and require dilutive financing.
Reported liquidity includes digital assets; the October 2027 runway assumes spending similar to first-half 2026 levels.

WatchKey bullets

Lucid-MS Phase 2 site activation and first enrollment

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $2 (p=45%)

Target spread vs base: +52% / -57%

Scenario probabilities

Bull Target: $4 (p=25%)Base Target: $2 (p=45%)Bear Target: $1 (p=30%)

Commentary

October coverage is favorable on trial start-up, but the verified SEC-filed release confirms a service agreement rather than patient dosing or results. The packet does not establish a reliable post-news price reaction, analyst revisions, or sufficient social and options coverage; zero-valued sentiment fields denote unavailable data, not neutral observations. The deterministic prior is neutral with low evidence quality and modest thesis change, supporting monitoring rather than a strong rerating call.

As of 2026-10-24 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Runway and financing reassessment as trial spending rises
Lucid-MS Phase 2 clinical evidence

Scenarios

Bull Target (Scenario probability)

$4 / p=25% prob

Base Target (Scenario probability)

$2 / p=45% prob

Bear Target (Scenario probability)

$1 / p=30% prob

Analysis 2026-10-24 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.30

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-03-31
Lucid-MS Phase 2 site activation and first enrollment
An October 6 SEC-filed company release confirms a study start-up agreement with Thermo Fisher Scientific's clinical research business. Start-up has begun, but first enrollment was not confirmed. The date is a monitoring estimate, not company guidance. [#SEC-6K-2026-10-06] https://www.sec.gov/Archives/edgar/data/1771885/000117184326006429/exh_991.htm
Prob 65.00% • Move 12.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Runway and financing reassessment as trial spending rises
2027-06-30
The company reported approximately $9.5 million in combined cash, cash equivalents and digital assets at June 30, including $3.65 million in cash and cash equivalents. Management projected runway to at least October 2027 assuming first-half 2026 burn and its current budget. Phase 2 spending or digital-asset volatility could change that estimate; the reassessment date is not an announced financing date. [#SEC-6K-2026-08-14] https://www.sec.gov/Archives/edgar/data/1771885/000117184326005524/exh_991.htm
Prob 70% • Move -20% • Priced-in 40%
Lucid-MS Phase 2 clinical evidence
2028-12-31
The planned trial will assess efficacy, safety and tolerability in progressive MS using clinical and radiological endpoints. A separate August report said a pilot MS imaging study had reached its enrollment midpoint and described preliminary PET signals; those findings do not establish Lucid-MS efficacy. A Phase 2 readout depends on enrollment and execution, and no readout date was confirmed. The date is a monitoring estimate. [#SEC-6K-2026-10-06] https://www.sec.gov/Archives/edgar/data/1771885/000117184326006429/exh_991.htm [#PR-EARNINGS-2026-08-03]
Prob 45% • Move 35% • Priced-in 20%

Risks

First-patient enrollment, trial completion and clinical benefit remain unconfirmed.
Phase 2 costs may accelerate cash use and require dilutive financing.
Reported liquidity includes digital assets; the October 2027 runway assumes spending similar to first-half 2026 levels. [#SEC-6K-2026-08-14] https://www.sec.gov/Archives/edgar/data/1771885/000117184326005524/exh_991.htm
Small market capitalization and loose peers make price targets highly sensitive to clinical and funding outcomes.

Peers

Symbol	Summary
BYSI	Same-sector, similar-market-cap candidate; a loose reference for development-stage biotech financing and event risk, not a confirmed MS-program comparable.
COCP	Same-sector, similar-market-cap candidate; useful only for broad microcap clinical-development risk, not indication-level valuation.
NEUP	Same-sector, similar-market-cap candidate; therapeutic and program comparability are unverified, limiting valuation usefulness.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-24

Loading AI feed…

Symbol

Summary

BYSI

Same-sector, similar-market-cap candidate; a loose reference for development-stage biotech financing and event risk, not a confirmed MS-program comparable.

COCP

Same-sector, similar-market-cap candidate; useful only for broad microcap clinical-development risk, not indication-level valuation.

NEUP

Same-sector, similar-market-cap candidate; therapeutic and program comparability are unverified, limiting valuation usefulness.